Liu Tianbo, Ma Li, Wang Yan, Wang Bo, Xu Yue, Gao Ying, Yu Ge, Gao Jialiang, Chen Jie
Department of Gynecological Oncology, Harbin Medical University Cancer Hospital, Harbin, 150081, People's Republic of China.
J Multidiscip Healthc. 2025 Jul 7;18:3891-3900. doi: 10.2147/JMDH.S525579. eCollection 2025.
With the advancement of medical technology, robotic-assisted surgery has emerged as a promising approach for the management of endometrial cancer (EC). This retrospective comparative study aimed to evaluate the efficacy, safety, and functional outcomes of two robotic systems-Kangduo (KD-RAS) and Da Vinci (DV-RAS)-in the treatment of EC.
This study included patients with stage T1 EC who underwent robotic-assisted surgery using either the Kangduo or Da Vinci system at Harbin Medical University Cancer Hospital. A comprehensive statistical analysis was conducted on their perioperative clinical data, encompassing preoperative, intraoperative, and postoperative parameters.
A total of 211 patients were enrolled in this study, including 125 in the KD-RAS group and 86 in the DV-RAS group. The surgical success rate was 100% in both groups, with no significant differences observed in preoperative baseline characteristics (P > 0.05). There were also no significant differences between the two groups in terms of blood loss, transfusion requirements, or Clavien-Dindo grade I/II complications (P > 0.05). However, the KD-RAS group exhibited longer operation time, console time, time to first flatus, and length of hospital stay compared to the DV-RAS group (P < 0.05). Notably, both total hospitalization costs and surgical expenses were significantly lower in the KD-RAS group than in the DV-RAS group (P < 0.05).
The Kangduo robotic system demonstrates comparable efficacy and equivalent safety profiles to the Da Vinci system, supporting its non-inferiority in clinical performance for the treatment of early-stage endometrial cancer.
随着医学技术的进步，机器人辅助手术已成为子宫内膜癌（EC）治疗的一种有前景的方法。这项回顾性比较研究旨在评估两种机器人系统——康多（KD-RAS）和达芬奇（DV-RAS）——在EC治疗中的疗效、安全性和功能结局。
本研究纳入了在哈尔滨医科大学附属肿瘤医院接受使用康多或达芬奇系统进行机器人辅助手术的T1期EC患者。对其围手术期临床数据进行了全面的统计分析，包括术前、术中和术后参数。
本研究共纳入211例患者，其中KD-RAS组125例，DV-RAS组86例。两组手术成功率均为100%，术前基线特征无显著差异（P>0.05）。两组在失血、输血需求或Clavien-Dindo I/II级并发症方面也无显著差异（P>0.05）。然而，与DV-RAS组相比，KD-RAS组的手术时间、控制台时间、首次排气时间和住院时间更长（P<0.05）。值得注意的是，KD-RAS组的总住院费用和手术费用均显著低于DV-RAS组（P<0.05）。
康多机器人系统在疗效和安全性方面与达芬奇系统相当，支持其在早期子宫内膜癌治疗的临床性能上不劣于达芬奇系统。
